» Articles » PMID: 23731777

Health-related Quality of Life Associated with Daytime and Nocturnal Hypoglycaemic Events: a Time Trade-off Survey in Five Countries

Overview
Publisher Biomed Central
Specialty Public Health
Date 2013 Jun 5
PMID 23731777
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hypoglycaemic events, particularly nocturnal, affect health-related quality of life (HRQoL) via acute symptoms, altered behaviour and fear of future events. We examined the respective disutility associated with a single event of daytime, nocturnal, severe and non-severe hypoglycaemia.

Methods: Representative samples were taken from Canada, Germany, Sweden, the United States and the United Kingdom. Individuals completed an internet-based questionnaire designed to quantify the HRQoL associated with different diabetes- and/or hypoglycaemia-related health states. HRQoL was measured on a utility scale: 1 (perfect health) to 0 (death) using the time trade-off method. Three populations were studied: 8286 respondents from the general population; 551 people with type 1 diabetes; and 1603 with type 2 diabetes. Respondents traded life expectancy for improved health states and evaluated the health states of well-controlled diabetes and diabetes with non-severe/severe and daytime/nocturnal hypoglycaemic events.

Results: In the general population, non-severe nocturnal hypoglycaemic events were associated with a 0.007 disutility compared with 0.004 for non-severe daytime episodes, equivalent to a significant 63% increase in negative impact. Severe daytime and nocturnal events were associated with a 0.057 and a 0.062 disutility, respectively, which were not significantly different.

Conclusions: This study applies an established health economic methodology to derive disutilities associated with hypoglycaemia stratified by onset time and severity using a large multinational population. It reveals substantial individual and cumulative detrimental effects of hypoglycaemic events - particularly nocturnal - on HRQoL, reinforcing the clinical imperative of avoiding hypoglycaemia.

Citing Articles

The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.

Elnaggar M, Mansinho J, Malkin S, Whitaker J, Hunt B, Glah D Diabetes Ther. 2025; .

PMID: 39969755 DOI: 10.1007/s13300-025-01691-1.


Improving outcomes with early and intensive metabolic control in patients with type 2 diabetes: a long-term modeling analysis of clinical and cost outcomes in Italy.

Arietti P, Boye K, Guidi M, Rachman J, Federici M, Raiola R J Diabetes Metab Disord. 2025; 24(1):58.

PMID: 39886102 PMC: 11780239. DOI: 10.1007/s40200-024-01553-w.


Cost-effective analysis focused on hypoglycemia of intermittent-scanning continuous glucose monitoring in type 1 diabetes adults: a ISCHIA randomized clinical trial.

Sakane N, Matsuhisa M, Kuroda A, Miura J, Hirota Y, Kato K Diabetol Int. 2025; 16(1):78-85.

PMID: 39877450 PMC: 11769919. DOI: 10.1007/s13340-024-00762-1.


Utilities Associated with the Treatment of Growth Hormone Deficiency (GHD): A Time Trade-off (TTO) Study in the UK and Canada.

Kirsch S, Butler G, de Fries Jensen L, Okkels A, Yssing C, Hakan-Bloch J Patient Relat Outcome Meas. 2025; 16():9-21.

PMID: 39811679 PMC: 11731022. DOI: 10.2147/PROM.S479705.


Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.

Asgharzadeh A, Patel M, Connock M, Damery S, Ghosh I, Jordan M Health Technol Assess. 2024; 28(80):1-190.

PMID: 39673446 PMC: 11664472. DOI: 10.3310/JYPL3536.


References
1.
Polonsky W, Davis C, Jacobson A, Anderson B . Correlates of hypoglycemic fear in type I and type II diabetes mellitus. Health Psychol. 1992; 11(3):199-202. DOI: 10.1037//0278-6133.11.3.199. View

2.
Szende A, Brazier J, Schaefer C, Deuson R, Isitt J, Vyas P . Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. Curr Med Res Opin. 2010; 26(8):1893-903. DOI: 10.1185/03007995.2010.494126. View

3.
Jaeschke R, Singer J, Guyatt G . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989; 10(4):407-15. DOI: 10.1016/0197-2456(89)90005-6. View

4.
Torrance G, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D . Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics. 1996; 9(6):535-59. DOI: 10.2165/00019053-199609060-00008. View

5.
Brod M, Christensen T, Thomsen T, Bushnell D . The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011; 14(5):665-71. DOI: 10.1016/j.jval.2011.02.001. View